Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X:
“Pumitamig, PD-L1 and VEGF bispecific antibody (BioNTech/ BMS)
- Rosetta CRC-203: phase 2/3, pumitamig plus chemotherapy versus bevacizumab plus chemotherapy
- Rosetta Gastric-204: phase 2/3, pumitamig plus chemotherapy versus nivolumab plus chemotherapy.
Gastrointestinal is next for pumitamig.”
More posts featuring Daisuke Kotani.